Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

Part of paid clinical trials in Bellevue, Nebraska.

Sponsor
Pfizer
Study ID
NCT07578649
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PF-08634404 — BIOLOGICAL
    Solution for IV infusion
  • Pembrolizumab — BIOLOGICAL
    Solution for IV infusion
  • Standard of Care Chemotherapy — DRUG
    Solution for IV infusion

Study Details

This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. Our bodies have a built-in DNA "spell-checker," called the mismatch repair (MMR) system, that fixes genetic mistakes. In most endometrial cancers, this system works normally, and these cancers are called MMR-proficient (pMMR). However, pMMR tumors are harder for the immune system to recognize and attack. When endometrial cancer has spread beyond the uterus or comes back after previous treatment, it is called advanced or recurrent endometrial cancer. This study is for adults with mismatch repair-pMMR advanced or recurrent endometrial cancer. Participants must meet key criteria, including: * Women who are 18 years or older, and not pregnant at the time of joining the study * pMMR endometrial cancer only * Measurable Stage III disease, Stage IV disease (with or without measurable disease) per FIGO staging, a system doctors use to describe how far cancer has spread in the body, or recurrent endometrial cancer * Has not received chemotherapy except for chemotherapy given after the main surgery and more than 6 months before relapse * Be in good enough health to receive study treatment. Approximately 600 adult women will be enrolled. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups, with about half in each group. The study is open, meaning both the doctors and participants know what treatment is being given. Participants will receive their assigned treatment through intravenous infusions (medicine is given directly into a vein). The treatment will be given in cycles. Experimental Group will receive new study medicine called PF-08634404 plus chemotherapy. It will be followed by PF 08634404 alone for up to 2 years (35 cycles). Control Group will receive an approved medicine called pembrolizumab plus chemotherapy. It will be followed by pembrolizumab alone for up to 2 years (20 cycles). The study will include regular visits for: * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will come for a final visit within a month to check their health and review any reactions. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records. This helps check health and any new treatments. * Tests will be done every 9 weeks during the first 104 weeks to see how the cancer is responding. After that, tests will be done every 12 weeks.

Key Dates

Start date
Oct 9, 2026
Status verified
Jun 2026
Primary completion
Jun 1, 2029
Completion
Jan 30, 2031

Study Design

Enrollment
600 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: PF-08634404 plus Chemotherapy
    PF-08634404 plus Chemotherapy, followed by PF-08634404 maintenance therapy
  • Active Comparator: Pembrolizumab plus Chemotherapy
    Pembrolizumab plus Chemotherapy, followed by Pembrolizumab maintenance therapy

Primary Outcome Measure

Progression-Free Survival (PFS) using RECIST v1.1 as assessed by Blinded Independent Central Review (BICR) [ Time Frame: Approximately 36 months ]

Central Contacts

Locations (4)

FacilityCityStateZIP
Nebraska Medicine - Bellevue Medical CenterBellevueNebraska68123
Nebraska Medicine - Cancer Center at Village Pointe Health CareOmahaNebraska68118
Nebraska Medicine - Nebraska Medical CenterOmahaNebraska68105
University of Nebraska Medical CenterOmahaNebraska68198

Find similar trials in Bellevue, NE

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Nebraska Medicine - Bellevue Medical Center· Bellevue, NENebraska Medicine - Cancer Center at Village Pointe Health Care· Omaha, NENebraska Medicine - Nebraska Medical Center· Omaha, NEUniversity of Nebraska Medical Center· Omaha, NE

Related Studies